The nation of Zimbabwe has turned down a significant US health deal worth $367m (272 million pounds) over five years over Washington's insistence on sensitive information.
This move became public after a official document from December was disclosed, which showed President Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesman later stated that the US was demanding access to health data for research and commercial gain while was unwilling to share the benefits from any future treatments.
"We will now turn to the challenging and unfortunate process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had furnished more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for more negotiations to reach a deal agreeable to both sides so the country's vital HIV programme can continue.
Wider Context
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a high court suspended a related health funding agreement following concerns were raised about the security of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to boost openness and accountability.
As per reports, Sixteen nations in Africa have so far agreed to these new agreements, constituting more than $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation could have provided significant advantages for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment through US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data over an extended period, without any equivalent promise of access to any scientific breakthroughs – such as new medicines or tests – that might result from that provided information," he stated.
"Effectively, our country would provide the basic resources for scientific discovery with no assurance that the final treatments would be available to our citizens if a future pandemic arise."
National Interest and Global Health
He also pointed out that the US's withdrawal from the global health body and its push of one-on-one deals were undermining systems already set up via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing system designed to manage future pandemics.
"This system is intended to guarantee that when a country provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage further discussions with our US partners on how subsequent collaboration might be structured in a way that honours the independence and interests of both nations."
Health Experts Reaction
A leading public health body expressed it recognised the official position, but suggested that talks need to persist considering a large portion of the nation's HIV programmes were funded by international support.
"Where specific concerns arise, including those involving data governance or agreement terms, these can often be resolved through technical clarification and negotiated safeguards," the group commented.
The halted deal emphasises the continuing debate between accepting vital foreign assistance and protecting a country's data in an increasingly data-driven world.